Lenvatinib as First-line Treatment of Hepatocellular Carcinoma in Patients with Impaired Liver Function in Advanced Liver Cirrhosis: Real World Data and Experience of a Tertiary Hepatobiliary Center

Cosma, LS; Weigand, K; Muller-Schilling, M; Kandulski, A

Kandulski, A (corresponding author), Univ Hosp Regensburg, Dept & Outpatients Dept Internal Med 1, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2021; 30 (2): 247

Abstract

Background & Aims: Lenvatinib is a multikinase inhibitor approved for systemic first line treatment of hepatocellular cancer (HCC) in patients wit......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索